AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21518647 — intervention group
Group type: EXPERIMENTAL
Intervention: Medihoney Antibacterial Medical Honey (2 mL of a 50/50 mixture of honey-saline solution once a day at night for 30 days)
Number of subjects: 34
Study 21518647 — intervention group
Group type: EXPERIMENTAL
Intervention: Medihoney Antibacterial Medical Honey
Number of subjects: 34
Study 21518647 — intervention group
Group type: COMPARATOR
Intervention: Control nostrils (no honey treatment)
Number of subjects: 34
Study 19143666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threshold group (phototherapy interrupted when TSB decreased to >/=1 mg/dL below limit)
Number of subjects: 52
Study 19143666 — intervention group
Group type: COMPARATOR
Intervention: Low-threshold group (phototherapy interrupted when TSB decreased to >/=3 mg/dL below limit)
Number of subjects: 52
Study 19143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of haemolysis or G6PD deficiency
Number of subjects: 52
Study 19143666 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of haemolysis or G6PD deficiency
Number of subjects: 52
Study 17532415 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n = 9)
Number of subjects: 44
Study 17532415 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-A receptor antagonist 2 mg/kg (n = 8)
Number of subjects: 44
Study 17532415 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (n = 44)
Number of subjects: 44
Study 15200755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus lovastatin 20 mg
Number of subjects: 48
Study 15200755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus lovastatin 40 mg
Number of subjects: 48
Study 15200755 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 20 mg alone
Number of subjects: 48
Study 15200755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11207020 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg b.i.d.
Number of subjects: 259
Study 11207020 — intervention group
Group type: COMPARATOR
Intervention: On-demand salbutamol (ODS)
Number of subjects: 259
Study 9765761 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 9765761 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 9765761 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 9765761 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 0
Study 9765761 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 0
Study 7976095 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for incompetent perforators
Number of subjects: 47
Study 7976095 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for incompetent perforators and ulcer excision followed by grafting
Number of subjects: 47
Study 7976095 — intervention group
Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 47
Study 3055325 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram administration (Group 1)
Number of subjects: 14
Study 3055325 — intervention group
Group type: COMPARATOR
Intervention: Disulfiram administration (Group 2)
Number of subjects: 14
Study 381616 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 0
Study 381616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30868622 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 155
Study 30868622 — intervention group
Group type: COMPARATOR
Intervention: Collagen Matrix (CMX)
Number of subjects: 155
Study 28153654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dextrose 5% with normal saline
Number of subjects: 193
Study 28153654 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 193
Study 25880166 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine (600 mg daily)
Number of subjects: 30
Study 25880166 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 23321403 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine combination (20/5 mg)
Number of subjects: 276
Study 23321403 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 276
Study 23321403 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan (20 mg)
Number of subjects: 276
Study 22967781 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term return to work (RTW)
Number of subjects: 117
Study 22967781 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term symptom remission
Number of subjects: 117
Study 20196699 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective feedback (CF)
Number of subjects: 21
Study 20196699 — intervention group
Group type: COMPARATOR
Intervention: Dual-screen guidance (DSG)
Number of subjects: 21
Study 20196699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both instructional conditions (CF and DSG)
Number of subjects: 21
Study 20196699 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-year-olds
Number of subjects: 21
Study 18050202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 168
Study 18050202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 16091994 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% w/v Avicel CL611
Number of subjects: 0
Study 16091994 — intervention group
Group type: COMPARATOR
Intervention: 2% w/v methylcellulose (MC)
Number of subjects: 0
Study 16091994 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing rate of 10 L/min
Number of subjects: 0
Study 12173800 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized ceftazidime 250 mg every 12 hours for up to 7 days
Number of subjects: 40
Study 12173800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study 12173800 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized ceftazidime
Number of subjects: 40
Study 10463708 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiobooklet (AB) decision aid
Number of subjects: 287
Study 10463708 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (control group)
Number of subjects: 287
Study 7614501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study 7614501 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 2203252 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g FO, supplying 2 g n-3 fatty acids
Number of subjects: 15
Study 2203252 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g FO, supplying 8 g n-3 fatty acids
Number of subjects: 15
Study 2203252 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g FO)
Number of subjects: 15
Study 379993 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 13
Study 379993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30991987 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised risk information in numeric form (e.g. 1 in 100) with use of infographics
Number of subjects: 30
Study 30991987 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised information described as 'highest', 'moderate' or 'lowest' risk with use of infographics
Number of subjects: 30
Study 30991987 — intervention group
Group type: COMPARATOR
Intervention: Positive test result, as is current practice
Number of subjects: 30
Study 29267553 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotics (Lactobacillus acidophilus 108 to 109 CFU, Lactobacillus rhamnosus 108 to 109 CFU, Lactobacillus casei 108 to 109 CFU, Bifidobacterium 108 to 109 CFU, fructo‐oligosaccharide (FOS) 6g)
Number of subjects: 91
Study 29267553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 29267553 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotics
Number of subjects: 91
Study 25985386 — intervention group
Group type: COMPARATOR
Intervention: Sigh at 0.5/min
Number of subjects: 20
Study 25985386 — intervention group
Group type: COMPARATOR
Intervention: Sigh
Number of subjects: 20
Study 23442831 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with pronase, dimethylpolysiloxane, and sodium bicarbonate 10 to 30 minutes before UGI endoscopy (Group B)
Number of subjects: 300
Study 23442831 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with pronase, dimethylpolysiloxane, and sodium bicarbonate 10 minutes before UGI endoscopy (Group A)
Number of subjects: 300
Study 23442831 — intervention group
Group type: COMPARATOR
Intervention: Premedication with pronase, dimethylpolysiloxane, and sodium bicarbonate 30 minutes before UGI endoscopy (Group C)
Number of subjects: 300
Study 21452030 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine radionovela
Number of subjects: 88
Study 19176275 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Therapy (CBT)
Number of subjects: 65
Study 19176275 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Supportive Therapy (ST)
Number of subjects: 65
Study 17101746 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release zolpidem (12.5 mg)
Number of subjects: 70
Study 17101746 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release zolpidem (10 mg)
Number of subjects: 70
Study 17101746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15233714 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict-oriented in-patient therapy
Number of subjects: 80
Study 15233714 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic out-patient therapy
Number of subjects: 80
Study 11414004 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on the blind positioning task
Number of subjects: 0
Study 11414004 — intervention group
Group type: COMPARATOR
Intervention: Changing the hand used in the task
Number of subjects: 0
Study 11414004 — intervention group
Group type: COMPARATOR
Intervention: Changing the location of the stick
Number of subjects: 0
Study 11414004 — intervention group
Group type: COMPARATOR
Intervention: Changing both hand and location
Number of subjects: 0
Study 9406884 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked gamma activity
Number of subjects: 0
Study 9406884 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced gamma activity (single trial analysis)
Number of subjects: 0
Study 9406884 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced activity for non-target trials
Number of subjects: 0
Study 9406884 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced activity for target responses
Number of subjects: 0
Study 8216413 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (ACT)
Number of subjects: 178
Study 8216413 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (NPX)
Number of subjects: 178
Study 3113339 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose group: 600 mg of tegafur p.o. daily and 1-2 mg of lentinan i.v. weekly
Number of subjects: 34
Study 3113339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group: 1200-800 mg of tegafur p.o. daily and 4 mg of lentinan i.v. weekly
Number of subjects: 34
Study 28948980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg) before extinction training
Number of subjects: 40
Study 28948980 — intervention group
Group type: COMPARATOR
Intervention: Placebo before extinction training
Number of subjects: 40
Study 27721049 — intervention group
Group type: EXPERIMENTAL
Intervention: Jasmine rice panicle extract (0.1-0.2%)
Number of subjects: 24
Study 27721049 — intervention group
Group type: EXPERIMENTAL
Intervention: Jasmine rice panicle extract (0.1% and 0.2%)
Number of subjects: 24
Study 24622044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention households from the IHIP trial
Number of subjects: 892
Study 24622044 — intervention group
Group type: COMPARATOR
Intervention: Control households from the IHIP trial
Number of subjects: 892
Study 24052035 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose endurance exercise (MOD: ≈ 30 min/day)
Number of subjects: 64
Study 24052035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose endurance exercise (HIGH: ≈ 60 min/day)
Number of subjects: 64
Study 24052035 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 64
Study 20973459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium fortified milk (400 ml daily for 16 weeks)
Number of subjects: 60
Study 20973459 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 60
Study 18097225 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI-containing regimen (zidovudine/lamivudine)
Number of subjects: 20
Study 18097225 — intervention group
Group type: COMPARATOR
Intervention: NRTI-sparing regimen (nevirapine)
Number of subjects: 20
Study 16060208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplementation from 1969-77
Number of subjects: 0
Study 16060208 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team approach
Number of subjects: 0
Study 12123405 — intervention group
Group type: EXPERIMENTAL
Intervention: Early advance care planning (ACP) facilitated by a trained nurse facilitator
Number of subjects: 61
Study 7674467 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine
Number of subjects: 120
Study 7674467 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 120
Study 2048623 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention related to leisure activities
Number of subjects: 40
Study 2048623 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 7316528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% anthralin
Number of subjects: 14
Study 7316528 — intervention group
Group type: COMPARATOR
Intervention: 0.05% anthralin
Number of subjects: 14
Study 7316528 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 14
Study 31531365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (EG)
Number of subjects: 49
Study 31531365 — intervention group
Group type: COMPARATOR
Intervention: No therapeutic intervention (CG)
Number of subjects: 49
Study 28977347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (150 kcal, 20 g whey protein, 800 IU vitamin D, 119 mL beverage)
Number of subjects: 149
Study 28977347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 kcal, nonnutritive, 119 mL)
Number of subjects: 149
Study 26501267 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (600 mg EPA and 625 mg DHA per day)
Number of subjects: 76
Study 26501267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 76
Study 25124011 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted remote echocardiography and teleconsultation
Number of subjects: 19
Study 25124011 — intervention group
Group type: COMPARATOR
Intervention: Standard of care consultation
Number of subjects: 19
Study 22691248 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri (108 CFU = 5 drops per day) for 60 days
Number of subjects: 50
Study 22691248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 drops per day) for 60 days
Number of subjects: 50
Study 19799559 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel neighboring sites model for methylation patterns
Number of subjects: 0
Study 19799559 — intervention group
Group type: COMPARATOR
Intervention: Previously developed stochastic models for methylation change
Number of subjects: 0
Study 16760200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization in elderly patients
Number of subjects: 1794
Study 16760200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization in US cohort
Number of subjects: 1794
Study 16760200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization in non-US cohort
Number of subjects: 1794
Study 16760200 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization in elderly who underwent catheterization in US cohort
Number of subjects: 1794
Study 16760200 — intervention group
Group type: COMPARATOR
Intervention: 90-day rates of death and death or myocardial infarction (MI) in elderly who underwent catheterization
Number of subjects: 1794
Study 12524069 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg daily)
Number of subjects: 48
Study 12524069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (50 mg) with ethinyl estradiol (EE)
Number of subjects: 48
Study 12524069 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 48
Study 12524069 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 48
Study 10501359 — intervention group
Group type: COMPARATOR
Intervention: Conventional spacer
Number of subjects: 88
Study 10501359 — intervention group
Group type: COMPARATOR
Intervention: Sealed 500 mL plastic bottle
Number of subjects: 88
Study 10501359 — intervention group
Group type: COMPARATOR
Intervention: Unsealed 500 mL bottle
Number of subjects: 88
Study 10501359 — intervention group
Group type: COMPARATOR
Intervention: 200 mL polystyrene cup
Number of subjects: 88
Study 10501359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised fenoterol (after initial treatment)
Number of subjects: 88
Study 8927681 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (two doses)
Number of subjects: 25
Study 8927681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1909692 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine A (5 mg/kg/day) for 12 weeks
Number of subjects: 22
Study 1909692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.05 ml/kg/day)
Number of subjects: 22
Study 6366807 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol cream 0.25%
Number of subjects: 60
Study 6366807 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol cream 0.1%
Number of subjects: 60
Study 6366807 — intervention group
Group type: COMPARATOR
Intervention: Dithranol ointment 0.25%
Number of subjects: 60
Study 31593254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support
Number of subjects: 0
Study 31593254 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29409778 — intervention group
Group type: EXPERIMENTAL
Intervention: TFOX regimen (docetaxel at 50 mg/m2)
Number of subjects: 506
Study 29409778 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX regimen (without docetaxel)
Number of subjects: 506
Study 29409778 — intervention group
Group type: EXPERIMENTAL
Intervention: TFOX regimen
Number of subjects: 506
Study 29409778 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX regimen
Number of subjects: 506
Study 26890969 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive and progressive heavy-resistance training (PRT)
Number of subjects: 35
Study 26890969 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control (CON)
Number of subjects: 35
Study 24726380 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental orthoses
Number of subjects: 16
Study 24726380 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthoses
Number of subjects: 16
Study 23127294 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of medical evidence for pain
Number of subjects: 102
Study 23127294 — intervention group
Group type: COMPARATOR
Intervention: Absence of medical evidence for pain
Number of subjects: 102
Study 23127294 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of psychosocial influences
Number of subjects: 102
Study 23127294 — intervention group
Group type: COMPARATOR
Intervention: Absence of psychosocial influences
Number of subjects: 102
Study 20568440 — intervention group
Group type: EXPERIMENTAL
Intervention: Expertise-based randomized controlled trial
Number of subjects: 0
Study 20568440 — intervention group
Group type: COMPARATOR
Intervention: Conventional randomized controlled trial
Number of subjects: 0
Study 18336721 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt abdominal entry
Number of subjects: 15000
Study 18336721 — intervention group
Group type: COMPARATOR
Intervention: Sharp abdominal entry
Number of subjects: 15000
Study 18336721 — intervention group
Group type: EXPERIMENTAL
Intervention: Exteriorisation of the uterus for repair
Number of subjects: 15000
Study 18336721 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal repair
Number of subjects: 15000
Study 18336721 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer closure of the uterus
Number of subjects: 15000
Study 18336721 — intervention group
Group type: COMPARATOR
Intervention: Double layer closure of the uterus
Number of subjects: 15000
Study 18336721 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 15000
Study 18336721 — intervention group
Group type: COMPARATOR
Intervention: Non-closure of the peritoneum
Number of subjects: 15000
Study 18336721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromic catgut for uterine repair
Number of subjects: 15000
Study 18336721 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin-910 for uterine repair
Number of subjects: 15000
Study 16109577 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electric Stimulation (FES)
Number of subjects: 48
Study 16109577 — intervention group
Group type: COMPARATOR
Intervention: Shoulder pads (Control)
Number of subjects: 48
Study 12443522 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulative therapy
Number of subjects: 9
Study 10825039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal bacille Calmette‐Guérin (BCG) vaccination
Number of subjects: 0
Study 7832226 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pass resolution perimetry
Number of subjects: 107
Study 7832226 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard perimetry
Number of subjects: 107
Study 7832226 — intervention group
Group type: COMPARATOR
Intervention: Overall agreement between high-pass resolution perimetry and standard perimetry
Number of subjects: 107
Study 2191876 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (cervical block with skin infiltration containing 200 micrograms adrenaline)
Number of subjects: 75